Objectives: Gastric adenomyoma is a benign, rare subepithelial tumor composed of mucosal elements and a prominent smooth muscle stroma commonly found in the stomach or duodenum occurring from the ages of 1 week to 81 years. Many cases are incidental findings on endoscopic examination or computed tomography (CT) scans; however, gastric adenomyoma can produce peptic-type ulcers and gastrointestinal (GI) tract bleeding. It is very difficult to diagnose this entity radiographically with non-specific CT findings; thus it is noteworthy for radiologists to recall this benign tumor. Whenever there is a gastric cystic subepithelial mass involving the distal portion of the stomach, it is important to remember gastric cystic adenomyoma. Methods: A 30-year-old woman presented to a teaching hospital in south Texas with abdominal pain. A CT scan showed narrowing of the distal stomach and antrum and a cystic lesion suggestive of a stromal tumor. A gastroduodenectomy specimen was obtained and processed at the surgical anatomic pathology laboratory. H&E and immunohistochemistry (IHC) studies were performed on formalin-fixed paraffin-embedded (FFPE) tissue. Results: Microscopic examination demonstrates a segment of stomach with gastric antral type mucosa and an underlying mass forming lesion consisting of scattered gastric type glands with focal metaplastic changes admixed with bundles of smooth muscle. Focally active duodenitis is present overlying the lesional tissue. Helicobacter pylori-like organisms are not identified. An immunohistochemical stain for CD117 is negative in the stromal cells. CD10 is positive in scattered inflammatory cells and negative in the stroma cells surrounding the entrapped glands. PAX-8 is negative in the entrapped glands, and CD34 highlights scatter vascular channels. There is no dysplasia or malignancy. Conclusion: This is a rare case of gastric adenomyoma, a benign hamartomatous tumor involving the antrum that must be considered when evaluating gastric subepithelial masses involving the distal portion of the stomach. Background: B-cell lymphoblastic leukemia (B-ALL) classically presents as a neoplastic proliferation of lymphoblasts expressing B-lineage markers and involving the bone marrow and peripheral blood. Immunophenotypic aberrancies are not uncommon in B-ALL, and coexpression of myeloid lineage markers is not unusual (86.5% of cases). Expression of T-cell lineage markers is less common (10% of cases), while the expression of the CD5 antigen is exceptionally rare. Patient: A 13-year-old girl presented with leukocytosis, anemia, and thrombocytopenia. Her peripheral blood flow cytometry was significant for 78% blasts. Bone marrow biopsy and cerebrospinal fluid analysis confirmed the diagnosis of CD5+ B-ALL with central nervous system (CNS) involvement, expressing complex cytogenetics. The patient received induction chemotherapy and achieved remission four weeks post-therapy. She relapsed after 13 months (87% blast in the bone marrow, with CNS involvement); neoplastic cells expressed CD45, CD10, CD19, CD5, CD20, CD22, CD34, and nuclear Tdt, with absent expression of cytoplasmic CD3. The patient underwent re-induction therapy, and again achieved remission. However, she relapsed a second time. CAR T-cell therapy was attempted; however, she experienced treatment complications. The patient ultimately succumbed to disseminated infection secondary to her disease 23 months following diagnosis. Results: A total of 16 cases of CD5+ B-ALL have been described in the literature, with detailed reports existing for only six cases. CD5+ B-ALL may occur more frequently in pediatric patients (65% n = 17), and be associated with a poor prognosis (67% n = 12). Cytogenic anomalies were commonly reported (70% n = 13). Conclusions: Although there are limited data available given the rarity ofCD5+ B-ALL, evidence suggests aberrant CD5 expression is a poor prognostic indicator. Additional research is required to determine whether CD 5+ B-ALL represents a uniquely aggressive subcategory of B-ALL. Furthermore, the CD5 antigen represents a potential target for monoclonal antibody therapy. Introduction: Histoplasma capsulatum is a fungus endemic to the Ohio and Mississippi River valleys that can cause pulmonary illness or disseminated infection. There are several tests for histoplasmosis, but serum and urine antigen (UAg, SAg) detection by enzyme-linked immunosorbent assay (ELISA) is most commonly performed due to its speed and accuracy. Studies have shown that UAg detection has higher sensitivity than SAg detection. Methods: At our hospital, UAg detection alone is usually ordered as an initial screen. However, SAg detection is ordered instead or in addition to UAg detection in some instances. The goal of this retrospective analysis was to determine whether SAg detection plays a useful role in the initial evaluation of a patient with suspected histoplasmosis. Results: From 1997 From -2016 UAg and 1,426 SAg tests were performed. From this data, we collected results from pairs of UAg and SAg tests completed on a patient within the same week (ie, paired specimens). Of 615 total paired specimens, 555 were concurrent negatives and 49 were concurrent positives, yielding 98% agreement between UAg and SAg detection. Eight of the 11 remaining paired specimens with discrepant UAg/SAg findings had available medical records. Based on infectious disease consult notes, culture data, and other patient data, we assigned six cases of UAg false positivity, one case of true positivity, and one case of false negativity. Conclusion: In the context of other studies, these findings support the use of UAg detection alone when first testing for suspected histoplasmosis. This aligns with the current practice of most physicians. Furthermore, this study indicates that SAg detection should be performed when a positive UAg result warrants confirmation, rather than as part of an initial screen. Objectives: Ulipristal acetate (UPA) is an oral selective progesterone-receptor modulator (SPRM). VENUS I (NCT02147197) was a phase 3, randomized, double-blind, placebo-controlled study assessing UPA for treatment of uterine fibroids (UF), which included a large proportion of black (self-identified) and obese (BMI ≥30 kg/m 2 ) patients. Methods: This study included a screening period, one 12-week treatment course, and a 12-week drug-free follow-up period. During treatment, premenopausal women (18-50 years) with ≥1 UF and cyclic excessive bleeding were randomized to receive once-daily UPA 5 mg, UPA 10 mg, or placebo. Endometrial thickness was assessed via transvaginal ultrasound. Endometrial biopsies were evaluated at baseline, mid treatment, and by the end of the follow-up period for malignancy and SPRM-associated endometrial changes (PAEC), defined as non-physiologic epithelial changes, extensive cysts, or vascular changes as assessed by three independent pathologists. Results: Of 157 patients randomized, 68.8% were black, and 50.3% were obese. Mean endometrial thickness (mm) at end of treatment (EoT) was similar for black (n = 75) vs non-black (n = 35) patients: UPA 5 mg (11.6 for both), UPA 10 mg (13.0 vs 12.2), placebo (11.0 vs 13.2); and for obese (n = 53) vs non-obese (n = 57) patients: 5 mg (11.9 vs 11.4), 10 mg (13.6 vs 11.9), placebo (10.7 vs 12.4). No evidence of malignancy was observed in endometrial
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